| 1.78 -0.04 (-2.2%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.36 | 1-year : | 2.62 |
| Resists | First : | 2.02 | Second : | 2.25 |
| Pivot price | 1.86 | |||
| Supports | First : | 1.65 | Second : | 1.38 |
| MAs | MA(5) : | 1.8  |
MA(20) : | 1.84 |
| MA(100) : | 2.16 |
MA(250) : | 2.47 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 20.6 |
D(3) : | 24.2 |
| RSI | RSI(14): 40.3 |
|||
| 52-week | High : | 4.67 | Low : | 1.6 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MBOT ] has closed above bottom band by 29.7%. Bollinger Bands are 23.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.82 - 1.83 | 1.83 - 1.84 |
| Low: | 1.74 - 1.75 | 1.75 - 1.76 |
| Close: | 1.76 - 1.78 | 1.78 - 1.8 |
Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.
Fri, 12 Jun 2026
Microbot Medical Inc Financial Disclosures & SEC Filings - TradingView
Fri, 12 Jun 2026
MBOT Stock Price, Quote & Chart - ChartMill
Tue, 09 Jun 2026
Microbot Medical secures Michigan healthcare system customer - Investing.com
Tue, 09 Jun 2026
Microbot Medical (NASDAQ: MBOT) adds major Michigan LIBERTY customer - Stock Titan
Tue, 09 Jun 2026
One of Michigan’s largest health systems adopts FDA-cleared vascular robot - Stock Titan
Tue, 09 Jun 2026
Microbot Medical® Announces a Notable Health System as the - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 6.716e+007 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 8,560 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.6e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 114.2 % |
| Return on Equity (ttm) | -18.4 % |
| Qtrly Rev. Growth | 105000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.22 |
| Qtrly Earnings Growth | -0.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0.6 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 7.68e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|